Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Spyre Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.63
5.21
3.89
0
0
18.7
2.33
0.89
0
0
Research and development
18.1
22.8
36.7
64.6
59.6
57.1
58.6
89.5
163
172
General and administrative
8.39
10.1
12.6
15.7
21.8
27.3
28.5
39.9
45.8
47.9
Operating expenses
26.5
32.9
49.4
80.3
81.5
84.4
87.1
243
209
210
Operating income
-21.9
-27.7
-45.5
-80.3
-81.5
-65.6
-84.8
-242
-209
-210
Other non-operating income
0.21
0.44
1.12
2.08
0.59
-0.01
0.83
-96.5
0.6
54.3
Pre-tax income
-78.3
-80.9
-65.7
-84
-339
-208
-155
Income tax
0
0
0
0
0
0.14
-0.14
-0.03
0.05
-0.02
Net income
-21.7
-27.2
-44.3
-78.3
-80.9
-65.8
-83.8
-339
-208
-155
EBITDA
-21.8
-27.4
-45.2
-79.9
-80.5
-64.1
-83.2
-242
-209
-210
EPS, basic
-55.54
-45.04
-53.29
-61.30
-38.03
-25.02
-24.86
13.76
EPS, diluted
-55.54
-45.04
-53.29
-61.30
-38.03
-25.02
-24.86
13.76
Shares, basic (weighted)
0.39
0.6
0.83
1.28
2.13
2.63
3.37
6.9
Shares, diluted (weighted)
0.39
0.6
0.83
1.28
2.13
2.63
3.37
6.9
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
47.7
12.8
22.5
19.3
90.1
15.1
34.9
189
89.4
85.7
Short-term investments
15.8
37.5
52.1
52.7
56.2
78
20.8
150
514
671
Other current assets
1.71
1.61
2.16
2.56
3.52
4.95
6.17
2.25
5.39
21.2
Total current assets
66.4
55
76.7
74.5
150
98.9
62.3
342
608
778
Property, plant and equipment
0.6
0.85
1.02
2.39
5.64
4.55
3.22
0
Lease right-of-use assets
4.73
4.23
3.81
3.43
0
Other non-current assets
0.04
0.23
0.05
0.07
0.12
0.84
0.68
0.01
0.01
0
Total assets
67.1
56.1
77.7
83.2
162
110
71.1
342
608
778
Accounts payable
0.17
0.39
0.66
3.15
2.25
3.32
0.68
0.9
Deferred revenue
0.07
0.02
0
3.58
0.52
0
Total current liabilities
3.97
5.63
10.2
18.4
16.4
20.1
14.7
32
54.1
58.7
Lease liabilities
4.71
5.13
4.61
4
0
Other non-current liabilities
0.13
0.11
0.07
0.03
0.21
0.02
0
0
Total liabilities
4.1
5.74
10.3
23.1
21.8
26
20.8
73.3
90.7
62.5
Paid-in capital
108
123
184
255
416
426
476
763
1,334
1,686
Retained earnings
-45.3
-72.5
-117
-195
-276
-342
-426
-764
-972
-1,128
Other comprehensive income
-0
-0.1
-0.03
0.05
0.01
-0.02
-0.05
0.3
0.18
0.87
Shareholders' equity
63
50.3
67.4
60.1
140
83.9
50.3
184
518
715
Total equity
63
50.3
67.4
60.1
140
83.9
50.3
184
518
715
Total liabilities and equity
67.1
56.1
77.7
83.2
162
110
71.1
342
608
778
Shares outstanding
0.54
0.67
0.96
1.16
1.92
49.4
2.61
36.1
60.3
78.2
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-21.7
-27.2
-44.3
-78.3
-80.9
-65.8
-83.8
-339
-208
-155
Depreciation and amortization
0.13
0.25
0.29
0.42
1
1.58
1.57
0.74
0
0
Stock-based compensation
1.22
2.49
4.28
4.88
6.26
8.04
7.11
25.7
44.8
37.6
Change in receivables
0.48
-1.86
3.08
0
0
-0.82
0.44
0.38
0
0
Change in payables
-0.01
0.16
0.24
2.58
-0.54
1.07
-2.64
Cash from operations
-18.8
-24.6
-32.2
-65.7
-75.8
-53.7
-80.1
-99.9
-157
-169
Capital expenditures
-0.21
-0.62
-0.42
-1.49
-4.28
-0.57
-0.04
0
0
Purchases of investments
-20.4
-64.1
-62.2
-91.9
-129
-133
-39.5
-167
-599
-522
Sales and maturities of investments
8.45
42.2
47.4
Cash from investing
-12.1
-22.5
-15.2
-1.74
-7.6
-22.6
57
-108
-353
-143
Stock issued
0
0
84.6
Cash from financing
49.4
12.2
57.1
65.7
155
1.39
42.7
361
411
309
Exchange rate effect
0
0.05
-0.02
-0.11
0.03
-0
0
Net change in cash
18.5
-34.9
9.64
-1.71
71.2
-75
19.4
153
-99.8
-3.7
Free cash flow
-19.1
-25.2
-32.6
-67.2
-80.1
-54.3
-80.2
-99.9
-157
Income taxes paid
-0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $85.69 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-16.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-15.3%
Net income / average total assets.
Return on invested capital (ROIC)
-16.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
38.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
142.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
38.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
27.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
121.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
36.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
18.5x
Current assets / current liabilities.
Quick ratio
18.1x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
18.1x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/B
6.86x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.86x
Market cap / tangible book value, when positive.
Earnings yield
-2.4%
Net income / market cap (the inverse of P/E).
What was Spyre Therapeutics, Inc.'s revenue in fiscal 2025?
Spyre Therapeutics, Inc. reported revenue of $0.0 for fiscal 2025.
Was Spyre Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $155.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.